Comprehensive Analysis of Lung Cancer Metastasis: Sites, Rates, Survival, and Risk Factors—A Systematic Review and Meta‐Analysis

Shilin Wang, Wen Tang, Fu Jin, Huanli Luo, Han Yang, Ying WangThe Clinical Respiratory Journal 2025 · DOI

TL;DR

This systematic review and meta-analysis provides a comprehensive overview of lung cancer metastasis, detailing common sites, incidence rates, survival outcomes, and crucial risk factors for both Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). The findings offer valuable insights for clinical decision-making and highlight the need for tailored treatment strategies based on metastatic patterns.

What Problem Does This Paper Address?

Lung cancer remains a leading cause of cancer-related mortality worldwide. A significant challenge in its management is metastasis, the spread of cancer cells to distant organs, which drastically alters prognosis and treatment efficacy. While localized tumors can often be treated effectively, metastatic disease significantly reduces survival rates. Understanding the intricate patterns of metastasis – where it spreads, how often, what factors increase the risk, and how it impacts survival – is crucial for improving patient outcomes. However, previous studies have often focused on specific aspects or lacked a comprehensive, systematic analysis across a large body of evidence. This paper aims to fill that gap by consolidating and analyzing data from numerous clinical trials to provide a detailed picture of lung cancer metastasis.

Methods

The researchers conducted a systematic review and meta-analysis of existing clinical trials. They searched major databases (Cochrane, Embase, Web of Science, PubMed, ClinicalTrial.gov) for studies reporting on lung cancer metastasis rates, risk factors for metastasis, and overall survival (OS) after metastasis. Two independent reviewers extracted data and assessed study quality using a standardized form and the Newcastle-Ottawa Scale. For quantitative synthesis, they employed random-effects models to account for potential heterogeneity in the data, calculating hazard ratios and confidence intervals. Statistical analyses were performed using Cochrane Review Manager and Stata MP software.

Datasets

This study did not introduce new datasets. Instead, it synthesized data from 115 previously published clinical trials that met their eligibility criteria. These trials provided data on:

  • Metastatic sites and rates (31 studies)
  • Risk factors for metastasis (23 studies)
  • Overall survival after metastasis (44 studies)
  • Risk factors for overall survival (37 studies)

Key Insights and Ideas

  • Distinct Metastatic Patterns: NSCLC and SCLC exhibit different primary metastatic sites. NSCLC commonly spreads to the brain, bone, adrenal gland, and liver, while SCLC shows a higher predilection for the liver, brain, and bone. This suggests that the "seed and soil" hypothesis, where cancer cells (seed) are influenced by the microenvironment of target organs (soil), likely plays a significant role.
  • Brain Metastasis is a Major Concern: Brain metastases are a frequent and significant complication for both NSCLC and SCLC, impacting survival.
  • EGFR Mutations as a Double-Edged Sword: While EGFR mutations are a risk factor for brain metastasis in NSCLC, they are also associated with a better overall survival, likely due to the effectiveness of targeted therapies like TKIs.
  • Prophylactic Cranial Irradiation (PCI) Shows Promise: PCI significantly reduces the incidence of brain metastases in both NSCLC and SCLC, highlighting its importance as a preventive measure.
  • Survival Varies Dramatically by Metastatic Site: Patients with liver or bone metastases generally have poorer survival outcomes compared to those with other metastatic sites. SCLC with liver metastasis had the shortest survival (3 months).
  • Multifaceted Risk Factors: Metastasis and survival are influenced by a complex interplay of factors including age, histological subtype (adenocarcinoma vs. squamous cell), genetic mutations (EGFR), treatment modalities (PCI, SRS, TKIs), and even gender and smoking status in SCLC.

Key Results

  • Prevalent Metastatic Sites:
    • NSCLC: Brain (29%), Bone (25%), Adrenal gland (15%), Liver (13%), Skin (3%).
  • SCLC: Liver (33%), Brain (30%), Bone (27%), Adrenal gland (10%), Pericardium (3%).
  • Risk Factors for Brain Metastases (NSCLC): Lung adenocarcinoma (RR 3.59), EGFR mutations (HR 1.68), and prophylactic cranial irradiation (PCI) (HR 0.36, significantly reducing risk).
  • Risk Factors for Brain Metastases (SCLC): Advanced age (≥65) (HR 0.70, inverse correlation), and PCI (HR 0.42, significantly reducing risk).
  • Median Overall Survival (OS) After Brain Metastasis:
    • NSCLC: 21.3 months (from diagnosis).
  • SCLC: 10.5 months (from diagnosis).
  • Key Survival Predictors:
    • NSCLC: Advanced age, extracranial metastases (negative impact); EGFR mutations, stereotactic radiosurgery (SRS) (positive impact).
  • SCLC: Male gender, smoking status, extracranial metastases, number of brain metastases (negative impact); whole-brain radiotherapy (WBRT) with boost, thoracic radiotherapy (positive impact).

Limitations and Future Work

The authors acknowledge several limitations:

  • Focus on Brain Metastasis: The meta-analysis of risk factors primarily concentrated on brain metastasis due to the limited availability of literature on determinants for other metastatic sites.
  • Retrospective Nature: The majority of included studies were retrospective, which inherently carries a risk of bias that cannot be fully detected or controlled.
  • Study Quality Variation: While overall risk of bias was assessed as low, the quality of individual studies varied, though sensitivity analyses suggested robust findings.
  • Observational Data: The reliance on observational cohort studies means findings are susceptible to confounding factors and selection bias, unlike randomized controlled trials (RCTs).

The authors suggest that future research should aim to generate more relevant RCTs to be included in meta-analyses, which would enable more reliable conclusions. They also highlight the need for further investigation into metastasis patterns and risk factors beyond the brain.

Summary updated

Abstract

This study provided insights into lung cancer metastasis. The results revealed the metastatic rates, risk factors, and OS to assist clinical decision-making.
BibTeX
@article{wang2025comprehensive,
  author = {Shilin Wang and Wen Tang and Fu Jin and Huanli Luo and Han Yang and Ying Wang},
  title = {{Comprehensive Analysis of Lung Cancer Metastasis: Sites, Rates, Survival, and Risk Factors—A Systematic Review and Meta‐Analysis}},
  journal = {The Clinical Respiratory Journal},
  year = {2025},
  doi = {10.1111/crj.70107},
}
Figure